Drug‐induced orthostatic hypotension: Cluster analysis of co‐prescription patterns in older people in UK primary care

Abstract

AbstractPurposeOver 250 medications are reported to cause orthostatic hypotension, associated with serious adverse outcomes in older adults. Studies suggest a harmful cumulative risk of orthostatic hypotension with multiple medication use. However, there is limited evidence on the potential for harm in practice, particularly which drugs is co‐prescribed and may increase risk of orthostatic hypotension.MethodsRetrospective cohort study and cluster analysis using general practice data from IQVIA Medical Research Data (IMRD) in patients aged ≥50 contributing data between 1 January 2018 and 31 December 2018. Thirteen drug groups known to be associated with orthostatic hypotension by mechanism, were analyzed and clusters generated by sex and age‐band.ResultsA total of 602 713 individuals aged ≥50 with 283 912 (47%) men and 318 801 (53%) women were included. The most prevalent prescriptions that might contribute to orthostatic hypotension were ACE inhibitors, calcium‐channel blockers, beta‐blockers, selective serotonin reuptake inhibitors and uroselective alpha‐blockers. We identified distinct clusters of cardiovascular system (cardiovascular system) drugs in men and women at all ages. cardiovascular system plus psychoactive drug clusters were common in women at all ages, and in men aged ≤70. cardiovascular system plus uroselective alpha‐blockers were identified in men aged ≥70.ConclusionsDistinct clusters of drugs associated with orthostatic hypotension exist in practice, which change over the life course. Our findings highlight potentially harmful drug combinations that may cause cumulative risk of orthostatic hypotension in older people. This may guide clinicians about the potential of synergistic harm and to monitor for orthostatic hypotension if using combinations of cardiovascular system drugs, cardiovascular system plus psychoactive drugs and/or alpha‐blockers—particularly in patients aged ≥70 or at high‐risk due to comorbidity. Future research should consider quantifying the risk of drug‐induced orthostatic hypotension with such drug combinations.